These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 35430800)

  • 1. The benefit of exercise rehabilitation guided by 6-minute walk test on lipoprotein-associated phospholipase A2 in patients with coronary heart disease undergoing percutaneous coronary intervention: a prospective randomized controlled study.
    Liu X; Zhou W; Fan W; Li A; Pang J; Chen Z; Li X; Hu X; Zeng Y; Tang L
    BMC Cardiovasc Disord; 2022 Apr; 22(1):177. PubMed ID: 35430800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prognostic Value of Lipoprotein-Associated Phospholipase A
    Yang L; Wang H; Zhang Y; Han T; Wang W
    Clin Appl Thromb Hemost; 2018 Jul; 24(5):822-827. PubMed ID: 29121808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein associated- phospholipase A2 in STEMI vs. NSTE-ACS patients: a marker of cardiovascular atherosclerotic risk rather than thrombosis.
    Verdoia M; Rolla R; Gioscia R; Rognoni A; De Luca G;
    J Thromb Thrombolysis; 2023 Jul; 56(1):37-44. PubMed ID: 37022507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein-associated phospholipase A2 is a risk factor for diabetic kidney disease.
    Hu Y; Li TT; Zhou W; Lu TT; Li FF; Ding B; Liu BL; Xie XJ; Ma JH
    Diabetes Res Clin Pract; 2019 Apr; 150():194-201. PubMed ID: 30904742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of monitoring exercise rehabilitation with target intensity on the patient with twice PCI: A case report.
    Liu X; Chen Y; Chen J; Li A; Zhong M; Zhou W; Tang L
    Medicine (Baltimore); 2023 Apr; 102(16):e33583. PubMed ID: 37083775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease.
    Wallentin L; Held C; Armstrong PW; Cannon CP; Davies RY; Granger CB; Hagström E; Harrington RA; Hochman JS; Koenig W; Krug-Gourley S; Mohler ER; Siegbahn A; Tarka E; Steg PG; Stewart RA; Weiss R; Östlund O; White HD;
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27329448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of canola or olive oil on plasma lipids, lipoprotein-associated phospholipase A
    Khandouzi N; Zahedmehr A; Nasrollahzadeh J
    Lipids Health Dis; 2020 Aug; 19(1):183. PubMed ID: 32795310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein-associated Phospholipase A2 and Coronary Heart Disease.
    Sofogianni A; Alkagiet S; Tziomalos K
    Curr Pharm Des; 2018; 24(3):291-296. PubMed ID: 29332572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyunsaturated omega-3 fatty acids reduce lipoprotein-associated phospholipase A(2) in patients with stable angina.
    Gajos G; Zalewski J; Mostowik M; Konduracka E; Nessler J; Undas A
    Nutr Metab Cardiovasc Dis; 2014 Apr; 24(4):434-9. PubMed ID: 24555913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry.
    Casas JP; Ninio E; Panayiotou A; Palmen J; Cooper JA; Ricketts SL; Sofat R; Nicolaides AN; Corsetti JP; Fowkes FG; Tzoulaki I; Kumari M; Brunner EJ; Kivimaki M; Marmot MG; Hoffmann MM; Winkler K; März W; Ye S; Stirnadel HA; Boekholdt SM; Khaw KT; Humphries SE; Sandhu MS; Hingorani AD; Talmud PJ
    Circulation; 2010 Jun; 121(21):2284-93. PubMed ID: 20479152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of serum lipoprotein-associated phospholipase A2, ischemia-modified albumin, and cystatin C in predicting coronary heart disease risk: a single center retrospective cohort study.
    Le QF; Liu J; Chen L
    Eur Rev Med Pharmacol Sci; 2023 Nov; 27(21):10730-10735. PubMed ID: 37975398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between Lp-PLA2 and in-stent restenosis after coronary stenting: a 3-year follow-up study.
    Sheng G; Zhou J; Zhang C; Wu C; Huang K; Qin X; Wu J
    Scott Med J; 2021 Nov; 66(4):178-185. PubMed ID: 34315293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Change of Inflammatory Factors in Patients with Acute Coronary Syndrome.
    Ma CY; Xu ZY; Wang SP; Peng HY; Liu F; Liu JH; Ren FX
    Chin Med J (Engl); 2018 Jun; 131(12):1444-1449. PubMed ID: 29893361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between Lp-PLA2 and coronary heart disease in Chinese patients.
    Yang L; Liu Y; Wang S; Liu T; Cong H
    J Int Med Res; 2017 Feb; 45(1):159-169. PubMed ID: 28222638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein-associated phospholipase A2 in coronary heart disease: Review and meta-analysis.
    Li D; Zhao L; Yu J; Zhang W; Du R; Liu X; Liu Y; Chen Y; Zeng R; Cao Y; Zeng Z; Zhao Z; Wu J
    Clin Chim Acta; 2017 Feb; 465():22-29. PubMed ID: 27956130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
    Ballantyne CM; Hoogeveen RC; Bang H; Coresh J; Folsom AR; Heiss G; Sharrett AR
    Circulation; 2004 Feb; 109(7):837-42. PubMed ID: 14757686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study.
    White HD; Simes J; Stewart RA; Blankenberg S; Barnes EH; Marschner IC; Thompson P; West M; Zeller T; Colquhoun DM; Nestel P; Keech AC; Sullivan DR; Hunt D; Tonkin A;
    J Am Heart Assoc; 2013 Oct; 2(5):e000360. PubMed ID: 24152981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic inhibition of lipoprotein-associated phospholipase A
    Prasad M; Lennon R; Barsness GW; Prasad A; Gulati R; Lerman LO; Lerman A
    Int J Cardiol; 2018 Feb; 253():7-13. PubMed ID: 29306475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein-associated phospholipase A2 and risks of coronary heart disease and ischemic stroke in the general population: A systematic review and meta-analysis.
    Li D; Wei W; Ran X; Yu J; Li H; Zhao L; Zeng H; Cao Y; Zeng Z; Wan Z
    Clin Chim Acta; 2017 Aug; 471():38-45. PubMed ID: 28514697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population.
    Cai A; Li G; Chen J; Li X; Li L; Zhou Y
    BMC Cardiovasc Disord; 2015 Feb; 15():14. PubMed ID: 25879827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.